AssetMark Inc
TXMD icon

AssetMark Inc’s TherapeuticsMD TXMD Stock Holding History

AssetMark Inc’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$8 – 3666
2026
Q1 		$8 Hold
4
– – ﹤0.01% 3431
2025
Q4 		$7 Hold
4
– – ﹤0.01% 3365
2025
Q3 		$4 Hold
4
– – ﹤0.01% 3178
2025
Q2 		$5 Hold
4
– – ﹤0.01% 2997
2025
Q1 		$4 Hold
4
– – ﹤0.01% 2617
2024
Q4 		$3 Hold
4
– – ﹤0.01% 2588
2024
Q3 		$7 Buy
+4
New +$7 ﹤0.01% 2244
2024
Q2 		– Sell
-1
Closed -$2 – 2233
2024
Q1 		$2 Buy
+1
New +$2 ﹤0.01% 1930

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AssetMark Inc's TXMD Position: Q2 2026 in Review

AssetMark Inc sold out of TherapeuticsMD (TXMD) in Q2 2026, closing a stake of 4 shares — an estimated $8 sold.

AssetMark Inc first reported a position in TXMD in Q1 2024 and held it in 8 quarters. The position peaked at $8 in Q1 2026. 44 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • AssetMark Inc reported no remaining TherapeuticsMD position as of Q2 2026 after selling out during the quarter.
  • AssetMark Inc sold 4 TherapeuticsMD shares in Q2 2026, an estimated $8.
  • AssetMark Inc first reported a position in TherapeuticsMD in Q1 2024 and held it in 8 quarters.
  • AssetMark Inc's TherapeuticsMD position peaked at $8 in Q1 2026.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.